Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia

Figures & data

Figure 1 Patient flow.

Abbreviations: AFA, afatinib; CTX, chemotherapy; DACO, dacomitinib; ECOG, Eastern Cooperative Oncology Group; EGFR+, epidermal growth factor receptor positive; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ERLO, erlotinib; GEFI, gefitinib; OSI, osimertinib; PD, disease progression.

Table 1 Baseline Characteristics of Patients in the Analysis Set (N = 351)

Characteristic	n (%)
Age (Mean, SD)	63.2 (11.0)
Gender
Male	135 (38.5)
Female	216 (61.5)
Ethnicity
Malay	137 (39.0)
Chinese	180 (51.3)
India	12 (3.4)
Non-Malaysian	22 (6.3)
Smoking status
Never smoker	283 (80.6)
Ex-smoker	59 (16.8)
Current smoker	7 (2.0)
ECOG performance status
0	70 (19.9)
1	173 (49.3)
2	51 (14.5)
3	33 (9.4)
4	22 (6.3)
TNM stage
IIIB and C	12 (3.4)
IVA	208 (59.3)
IVB	131 (37.3)
Histological subtype of NSCLC
Adenocarcinoma	340 (96.9)
Non-adenocarcinoma	11 (3.1)
EGFR mutation
Ex19Del	195 (55.6)
Ex21 L858R	113 (32.2)
Others	43 (12.3)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TNM, tumour nodes and metastasis.

Figure 2 Time on treatment (TOT) according to first-line treatment excluding patients lost to follow-up (N=279).

Figure 3 Overall survival (OS) according to first-line treatment excluding patients lost to follow-up (N=250).

Figure 4 Overall survival (OS) after first-line first- and second-generation EGFR TKIs with and without third-generation EGFR-TKI.

Table 2 Second-Line Treatment in Patients Who Progressed After First-Line Treatment

First-Line Treatment	N	PD	Genetic Testing**	Second-Line Treatment
				Yes	CTX	EGFR TKI		Others
						1st or 2nd Generation ±CTX	3rd Generation ±CTX
CTX*	27	26	0	22	2	19	1	0
1st or 2nd generation EGFR TKI ±CTX	280	229	83	138	45	34	57	2
3rd generation EGFR TKI±CTX	44	24	3	14	6	4	1	3
Total	351	279	86	174	53	57	59	5

Note: *CTX alone; **Number of patients with no genetic testing in each category of first-line treatment regime= number of patients with PD minus number of patients with genetic testing.